Clinical Trials Detail

Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR+ NSCLC

A Randomized Phase II/III Trial of Afatinib + Cetuximab vs Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR+ NSCLC

Study #:


Anatomic Site: Lung
Histology: Non-Small Cell Lung Cancer (NSCLC)
Mutation: EGFR (exon 19 deletion; econ 21 (L858R) substitution)
Stage: Stage IV or recurrent NSCLC
Treatment Phase: Patients have histologically or cytologically confirmed stage IV or recurrent NSCLC and documented presence of mutation. Patients must not have received any prior systemic anticancer therapy.
Study Link:

Clinical Trial Categories

  • Lung